๐ŸŽ—๏ธ OncologyTablet (oral)

    Zelboraf

    VEMURAFENIB

    Zelboraf is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation, and for Erdheim-Chester disease with BRAF V600 mutation.

    Form

    Tablet (oral)

    Uses

    2

    Side effects

    4

    Category

    Oncology

    01

    What is Zelboraf used for?

    • Treatment of unresectable or metastatic melanoma with BRAF V600E mutation
    • Treatment of Erdheim-Chester disease with BRAF V600 mutation
    02

    VEMURAFENIB side effects

    Common side effects of VEMURAFENIB include:

    New primary cutaneous malignancies
    Photosensitivity
    Arthralgia
    Fatigue
    CommonModerateLess common
    03

    VEMURAFENIB warnings & precautions

    • Risk of new primary cutaneous malignancies: perform dermatologic evaluations prior to and during treatment.
    • QT prolongation has been observed. Monitor ECG before and during treatment.

    Loading FDA dataโ€ฆ

    04

    Frequently asked questions

    05

    Related medications

    Share

    Share this drug info.

    Help friends and family understand Zelboraf in plain language.

    Disclaimer: This information is sourced from the FDA openFDA database and is provided for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before starting or changing medication.